Compare Gilead Sciences, Inc. (GILD) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs VICI Properties Inc — how do they compare? Gilead Sciences, Inc. trades at $133.55 (market cap $163.51B), while VICI Properties Inc trades at $26.98 (market cap $28.97B). The key difference: Gilead Sciences, Inc. is far larger — about 5.6× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.84%). Which is the better fit depends on your goals.
| GILD | VICI | |
|---|---|---|
Market Cap | $163.51B | $28.97B |
Sector | Health | Real Estate |
52-Week High | $155.80 | $33.93 |
52-Week Low | $108.22 | $25.94 |
Enterprise Value | $178.05B | $46.19B |
Dividend Yield | 2.49% | 6.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
VICI Properties trades at $26.72, up 1.67% with a bearish technical signal despite strong fundamentals including a 76.83% net margin and 11.33% ROE. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed. The company maintains robust cash flow with $2.51B from operations in 2025 and recently completed a Canadian portfolio acquisition, supporting its 6.62% dividend yield.
The stock presents value with a P/E of 9.01 below sector averages, but faces headwinds from tenant concentration risks and technical weakness. Analyst consensus remains strongly bullish with a $30 price target, suggesting 12% upside potential if operational stability persists amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
